Qilu Pharmaceutical’s QL1604 Plus Chemotherapy Shows Promise in Phase II Study
China-based Qilu Pharmaceutical announced that the results of the Phase II study assessing its QL1604...
Company
China Health Group Signs Framework Agreement with Mingcheng Wanda Pharma
China Health Group Ltd (HKG: 0673) announced the signing of a framework agreement with compatriot...
Hybio Receives Ethical Approval for HY3000 COVID-19 Nasal Spray Phase II Study
China-based Hybio Pharmaceutical Co., Ltd (SHE: 300199) announced receiving ethical approval for a Phase II...
Clover Biopharmaceuticals’ COVID-19 Vaccine SCB-2019 Included in China’s Emergency Use Program
China-based vaccine specialist Clover Biopharmaceuticals, Ltd (HKG: 2197) announced the inclusion of its COVID-19 vaccine...
Microport EP Medtech’s Pressure Monitoring Catheter Approved by NMPA
Shanghai Microport EP Medtech Co., Ltd’s disposable pressure monitoring magnetic positioning radiofrequency catheter has been...
Henlius Biotech Doses First Patient in Phase I Study for HLX60 in China
Shanghai Henlius Biotech Inc. (HKG: 2696) announced the first patient dosing of a Phase I...
Fudan Team Presents Ribociclib Phase II Bridging Study Results at ESMO Asia
A Fudan University Shanghai Cancer Center team led by Shao Zhimin made an oral presentation...
Hansoh’s EGFR Inhibitor Ameile Filed for EMA Review by Partner EQRx
China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) announced that a market filing for its...
Sinocelltech’s SCTV01C Vaccine Included in China’s Emergency Use Program
China-based Sinocelltech Group Ltd (SHA: 688520) announced the inclusion of its recombinant novel coronavirus alpha+beta...
Lynk Pharmaceuticals Doses First Patient in Phase II Study for LNK01003
China-based Lynk Pharmaceuticals (Hangzhou) Co., Ltd announced first patient dosing in a Phase II clinical...
Lavamed Secures USD 40M in Angel and Series A Financing Rounds
Lavamed, a high-end neurointervention device maker based in Suzhou, has successively closed angel and Series...
Innovent Biologics Doses First Volunteer in Orismilast Phase I Study
China-based Innovent Biologics Inc., (HKG: 1801) and Denmark-based partner Union Therapeutics A/S revealed that a...
Daiichi Sankyo Doses First Patient in Global Phase III TROPION-Lung08 Study
Japan-based Daiichi Sankyo Inc. (TYO: 4568) announced the first patient dosed in the global multi-center...
Tsingke Biotech Secures RMB 400M Series B Financing for Expansion
Beijing Tsingke Biotech Co., Ltd. a gene synthesis company based in Beijing, reportedly raised RMB...
China Medical System Licenses Opzelura from Incyte for Greater China and Southeast Asia
China Medical System Holdings (CMS; HKG: 0867) announced the establishment of a licensing agreement with...
SAFE Raises RMB 500M in Series D Financing to Expand CRO Services
Serve Accurate Faithful Evaluation (SAFE), a contract research organization (CRO) co-founded by the Chinese Academy...
Peijia Medical Enrolls First Patient in GeminiOne TEER System Study
China’s Peijia Medical Ltd (HKG: 9996) announced first patient enrollment in a multi-center clinical study...
NMPA Approves Henlius’ HLX04 Biosimilar for Lung and Colorectal Cancer
The National Medical Products Administration (NMPA) website indicates that China-based Shanghai Henlius Biotech’s (HKG: 2696)...
Yifan Pharma Transfers F-627 Distribution Rights in Germany to Apogepha
China-based Yifan Pharmaceutical Co., Ltd (SHE: 002019) announced the transfer of exclusive distribution rights in...
Pyxis Oncology Receives FDA Approval for Biosion’s PYX-106 Clinical Trials
China-based Biosion, Inc’s US partner Pyxis Oncology, Inc. (NASDAQ: PYXS) announced receiving clinical trial approval...